Consolidated Portfolio Review Corp Novartis Ag Transaction History
Consolidated Portfolio Review Corp
- $448 Billion
- Q3 2024
A detailed history of Consolidated Portfolio Review Corp transactions in Novartis Ag stock. As of the latest transaction made, Consolidated Portfolio Review Corp holds 2,598 shares of NVS stock, worth $251,564. This represents 0.07% of its overall portfolio holdings.
Number of Shares
2,598
Previous 2,598
-0.0%
Holding current value
$251,564
Previous $277 Million
8.04%
% of portfolio
0.07%
Previous 0.06%
Shares
4 transactions
Others Institutions Holding NVS
# of Institutions
1,438Shares Held
133MCall Options Held
1.12MPut Options Held
1.83M-
Dodge & Cox San Francisco, CA12.2MShares$1.18 Billion0.85% of portfolio
-
Primecap Management CO Pasadena, CA12MShares$1.16 Billion1.03% of portfolio
-
Dimensional Fund Advisors LP Austin, TX8.09MShares$784 Million0.23% of portfolio
-
Morgan Stanley New York, NY6.98MShares$676 Million0.06% of portfolio
-
Loomis Sayles & CO L P5.77MShares$559 Million0.87% of portfolio
About NOVARTIS AG
- Ticker NVS
- Exchange OTC
- Sector Healthcare
- Industry Drug Manufacturers—General
- Shares Outstandng 2,151,000,064
- Market Cap $208B
- Description
- Novartis AG researches, develops, manufactures, and markets healthcare products worldwide. The company operates through two segments, Innovative Medicines and Sandoz. The Innovative Medicines segment offers prescription medicines for patients and healthcare providers. It also provides ophthalmology, neuroscience, immunology, hepatology, dermatol...